Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• lymphocyte predominant Hodgkin´s lymphoma (histologically proven)

• clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR > 50mm/h)

• age 18 - 75

• WHO performance status 0-3

• normal organ function

• written informed consent

Exclusion Criteria:

• classical Hodgkin´s lymphoma

• composite lymphoma

• leucocytes < 3000/µl

• thrombocytes < 100.000/µl